STLN · Starling Oncology, Inc.
The latest filing states the doubt was alleviated.
“the Company conducted an evaluation as to whether there were conditions and events, considered in the aggregate, which raised substantial doubt as to its ability to continue as a going concern within one year after the date of the issuance of such financial statements. The Company had cash and cash equivalents of $41,094 and an accumulated deficit of $283,700 at June 30, 2026, and a net loss of $12,281 and net cash provided by operations of $9,725 for the six months ended June 30, 2026. The Company has concluded that it will have sufficient liquidity to fund its operations for at least one year from the date these consolidated financial statements are issued.”View the 10-Q filed Aug 6, 2026
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Starling Oncology posted Q2 2026 revenue up 35% to $161.3M, turned positive on adjusted EBITDA at the top of guidance, completed a non-dilutive refinancing that extends debt maturities to 2031, raised full-year 2026 revenue and gross profit guidance while narrowing adjusted EBITDA, and announced new capitated contracts adding roughly 310,000 lives and ~$56M of annualized capitation revenue.
- + Q2 revenue rose 34.6% YoY to $161.3M, driven by 57.6% growth in specialty pharmacy revenue.
- + Raised 2026 revenue guidance to $650–$670M and gross profit to $105–$110M.
- + H1 2026 free cash flow of $9.5M vs. a $(14.6M) use a year ago, an improvement of over $24M.
- − MLR on capitated contracts rose to 85.5% from 71.0% a year ago, with guidance of 80–90% over the next 12 months.
- − Patient services gross profit fell ~57% YoY to $2.1M from $4.7M, driven by clinical labor buildup, conservative FFS approach, and MLR step-up.
- − Q3 2026 adjusted EBITDA guided to a muted $0.5M–$1.5M as 230,000 new members are onboarded and ramp.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 229K | Q2 2026 | — |
| Affiliated and Network Clinics | 301 | Three Months Ended June 30, 2026 | — |
| Capitated lives added (exclusivity agreement in California) | 230,000 | Q2 2026 | — |
| Clinics and network locations of care | 100 | Q2 2026 | — |
| Employed and network clinicians | 400 | Q2 2026 | — |
| Free Cash Flow non-GAAP | $9.53M | Six Months Ended June 30, 2026 | — |
| Lives under value-based contracts | 2.1M | Three Months Ended June 30, 2026 | — |
| Markets | 17 | Three Months Ended June 30, 2026 filing | — |
| Medical loss ratio related to capitated contracts non-GAAP | 85.5% | Q2 2026 | — |
| Patients in population served | 2.1M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STLN
this stock
Starling Oncology, Inc.
|
$678.76M | +78.4% | +27.8% | — | 6.9% |
|
HCA
HCA Healthcare, Inc.
|
$96.64B | -8.6% | +7.1% | 15.0 | 2.9% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.92B | -13.3% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.91B | +30.1% | +0.9% | 10.0 | 2.5% |
|
EHC
Encompass Health Corp
|
$12.18B | +12.9% | +10.5% | 20.1 | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STLN | -4.7% | +6.4% | +92.4% | +0.5% | +78.4% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -4.4% | +6.8% | +80.2% | -0.5% | +65.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.